HVivo and Johnson & Johnson have co-led a series A round to support a clinical trial for a preventative treatment of colds and flus.
Prep Biopharm, a UK-based developer of therapies for respiratory infectious diseases, closed a series A round at £21m ($32.4m) yesterday, co-led by virology contract researcher HVivo and pharmaceutical firm Johnson & Johnson.
Johnson & Johnson invested through its corporate venturing subsidiary Johnson & Johnson Innovation. The two corporates were joined by assorted angel investors.
Prep Biopharm is developing treatments for respiratory infectious illnesses such as colds and flus.
The series A capital will support the completion of a phase 2a…
